ERS Genomics CEO John E. Milad explores how the shift from bespoke experimentation towards engineering discipline is changing the next phase of synthetic biology in the latest Monthly Cut.
Public source
Publisher name
Public post
Ten years ago, getting CRISPR to work reliably in a new production organism could be a significant part of the challenge. Today, for many industrial microbes, the pictur…
Company
ERS Genomics
The global CRISPR/Cas9 licensing leader
- Industry
- Biotechnology Research
- Location
- San Francisco, US
- Company size
- 11–50 employees
About ERS Genomics
ERS Genomics was formed to commercialise the foundational CRISPR-Cas9 intellectual property held by co-inventor, co-owner and Nobel Prize-winner Dr. Emmanuelle Charpentier. Licenses are available in multiple fields of use. CRISPR-Cas9 is a revolutionary new genome editing technology, which offers significant advantages in speed, efficiency and cost over earlier genome editing methods. Our team has decades of experience in the field of genome editing and its application, in business development and licensing, licensing preclinical and clinical stage therapeutic products and drug delivery technologies, genome editing technologies as well as overseeing research and development. To learn more about acquiring your license, contact us today.
See moreLatest activity
Latest activity from ERS Genomics
4 signals
Research & Knowledge
ERS Genomics published a new drug-design framework that learns directly from every compound synthesised in the lab, including failures and candidates rejected on developability grounds.
Research & Knowledge
ERS Genomics CEO John E. Milad explores how CRISPR has become part of the core toolkit of synthetic biology and industrial bioproduction in The Monthly Cut
Research & Knowledge
ERS Genomics published an article exploring challenges in synthetic biology and biomanufacturing in The Monthly Cut, The SynBio Scale-Up
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Synbio Technologies
Synbio Technologies used a dual-promoter strategy to independently drive the expression of two sgRNAs in its dual-sgRNA library case study.
Research & Knowledge
Twist Bioscience
Twist Bioscience published a white paper describing an approach for generating accurate, uniform gene libraries up to 1.8 kb in length using Twist Bioscience's Gene Pools technology.
Research & Knowledge
Prolific Machines
Prolific Machines Head of Synthetic Biology Kiana Mohajeri-Stickels breaks down how the company's cell line engineering approach uses light-controlled gene expression to solve CLD's persistent bottlenecks.
Research & Knowledge
New England Biolabs
New England Biolabs published a study introducing Mucilaginibacter paludis Argonaute (Mpa Ago) as a programmable RNA restriction enzyme that cleaves messenger RNAs at precise, user-defined sites without CRISPR-Cas sequence constraints.
Research & Knowledge
Broken String Biosciences